News and Announcements
Shivom Begins Its Official Bounty Program
- Published April 04, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
-
Shivom will be allocating 30 million tokens to the Bounty Pool (equivalent to 4200 ETH).
-
The program will run until the end of the Token Sale which begins on April 16th, 2018
With our OmiX (OMX) token launch approaching, we are expanding our community, ensuring that more and more people can benefit from getting their hands on our tokens!
We will be allocating 30 million tokens to the Bounty Pool (equivalent to 4200 ETH).
In order for a user to participate in the Bounty Program, they must become a member of Shivom’s Telegram Group.
A few things to remember before joining:
-
The Bounty program is NOT open to US Residents
-
The program will run until the end of the Token Sale which begins on April 16th, 2018.
-
The Bounties will be paid within 30 Days after the end of the Token Sale
Following is the planned Bounty allocation:
With only a couple weeks until our Toke Sale, don’t miss your opportunity to get on board now! Find out more on the bounty distribution across social media channels (found on Shivoms company listing page).
Join us in powering the next era of genomics!
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
